Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH – Get Free Report) CFO William J. Peters sold 60,743 shares of Amphastar Pharmaceuticals stock in a transaction on Wednesday, September 6th. The shares were sold at an average price of $51.75, for a total value of $3,143,450.25. Following the completion of the sale, the chief financial officer now directly owns 101,360 shares of the company’s stock, valued at $5,245,380. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Amphastar Pharmaceuticals Stock Down 2.4 %
NASDAQ:AMPH traded down $1.23 during midday trading on Friday, reaching $50.01. The company had a trading volume of 252,718 shares, compared to its average volume of 363,470. Amphastar Pharmaceuticals, Inc. has a 12-month low of $26.76 and a 12-month high of $67.66. The firm has a market capitalization of $2.41 billion, a price-to-earnings ratio of 26.28 and a beta of 0.84. The company has a current ratio of 1.53, a quick ratio of 1.11 and a debt-to-equity ratio of 0.83. The stock’s fifty day simple moving average is $57.17 and its 200-day simple moving average is $46.93.
Amphastar Pharmaceuticals (NASDAQ:AMPH – Get Free Report) last posted its quarterly earnings results on Tuesday, August 8th. The company reported $0.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.52 by $0.06. Amphastar Pharmaceuticals had a return on equity of 20.12% and a net margin of 18.85%. The company had revenue of $145.71 million for the quarter, compared to analyst estimates of $137.20 million. On average, sell-side analysts anticipate that Amphastar Pharmaceuticals, Inc. will post 2.5 earnings per share for the current fiscal year.
Institutional Trading of Amphastar Pharmaceuticals
Several hedge funds have recently added to or reduced their stakes in AMPH. Royce & Associates LP purchased a new stake in shares of Amphastar Pharmaceuticals in the 1st quarter valued at approximately $837,000. LSV Asset Management increased its holdings in Amphastar Pharmaceuticals by 210.3% in the first quarter. LSV Asset Management now owns 33,200 shares of the company’s stock valued at $1,245,000 after buying an additional 22,500 shares during the last quarter. New York Life Investment Management LLC raised its stake in Amphastar Pharmaceuticals by 12.4% in the fourth quarter. New York Life Investment Management LLC now owns 15,761 shares of the company’s stock valued at $442,000 after buying an additional 1,741 shares in the last quarter. Handelsbanken Fonder AB purchased a new stake in Amphastar Pharmaceuticals during the 1st quarter worth about $338,000. Finally, Everence Capital Management Inc. acquired a new position in shares of Amphastar Pharmaceuticals during the 1st quarter worth about $243,000. Institutional investors and hedge funds own 65.09% of the company’s stock.
Analysts Set New Price Targets
AMPH has been the subject of a number of research analyst reports. Piper Sandler raised their target price on Amphastar Pharmaceuticals from $66.00 to $71.00 in a report on Wednesday, August 9th. StockNews.com lowered shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday. Finally, Jefferies Financial Group initiated coverage on shares of Amphastar Pharmaceuticals in a research note on Tuesday, July 25th. They set a “buy” rating and a $70.00 target price on the stock.
Get Our Latest Research Report on Amphastar Pharmaceuticals
Amphastar Pharmaceuticals Company Profile
(Get Free Report)
Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredient (API).
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Amphastar Pharmaceuticals, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Amphastar Pharmaceuticals wasn’t on the list.
While Amphastar Pharmaceuticals currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report